Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients

Radiation Oncology

Luca Cozzi³  Antonella Fogliata³  Feng-Ling Chang²  Na-Na Chung²  Wei-Chung Hsu¹  Po-Ming Wang² 

[1] Department of Healthcare Administration, Asia University, Taichung, Taiwan;Department of Radiation Oncology, Cheng-Ching General Hospital, Taichung, Taiwan;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

关键词: Radiotherapy;    VMAT;    RapidArc;    Hepatocelluar Carcinoma;   

Others  :  1154948
DOI  :  10.1186/1748-717X-7-207

 received in 2012-06-22, accepted in 2012-12-03,  发布年份 2012

【 摘 要 】

Background

To report early outcome and toxicity for inoperable patients with hepatocellular carcinoma (HCC) treated with volumetric modulated arc therapy (VMAT).

Methods

One hundred and thirty eight patients were retrospectively analysed. Dose prescription ranged from 45 to 66Gy with conventional fractionation regime. Based on AJCC staging, 88.4% presented stage III or IV. Two-thirds (69.6%) were Child-Pugh stage A, the remaining were stage B. According to Barcelona Clinic Liver Cancer staging, 72.5% of patients were classified as stage C.

Results

Median age was 66 years, median tumor volume was 516cm³ (28 to 3620cm³). The most patients (83%) were treated with 60Gy. Median follow-up time was 9 months. One-year overall survival rate was 45% (100% for AJCC stage I, 83% for stage II, 45% for stage III and 28% for stage IV), median survival was 10.3 months (95% C.I. 7.2-13.3). Local control was achieved in 94% (of 109 assessable patients), stable disease in 29%, partial response in 53%, complete response in 11%, and progression in 6%. Radiation-induced liver disease was observed in 34 patients (25%). Gastrointestinal grade 3 toxicity was modest with a total of 17 (12.3%) cases for all endpoints.

Conclusions

Clinical results could suggest to introduce VMAT as an appropriate technique for the patients with HCC.

【 授权许可】

   
2012 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the united states from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
• [2]El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the united states. N Engl J Med 1999, 340:745-750.
• [3]Bujold A, Dawson LA: Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiother 2011, 15:54-63.
• [4]Dawson LA: Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011, 21:241-246.
• [5]Feng M, Ben-Josef E: Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011, 21:271-277.
• [6]Guy J, Kelley RK, Roberts J, et al.: Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012, 10:354-362.
• [7]Lawrence TS, Robertson JM, Anscher MS, et al.: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31:1237-1248.
• [8]Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005, 15:279-283.
• [9]Pan CC, Kavanagh BD, Dawson LA, et al.: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76:S94-S100.
• [10]Park HC, Seong J, Han KH, et al.: Dose–response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155.
• [11]Cheng JC, Wu JK, Huang CM, et al.: Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003, 56:229-234.
• [12]Eccles CL, Bissonnette JP, Craig T, et al.: Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int J Radiat Oncol Biol Phys 2008, 72:582-588.
• [13]Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008, 35:310-317.
• [14]Fogliata A, Clivio A, Nicolini G, et al.: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 2008, 89:254-262.
• [15]Scorsetti M, Alongi F, Castiglioni S, et al.: Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol 2011, 6:113. BioMed Central Full Text
• [16]Kuo YC, Chiu YM, Shih WP, et al.: Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy. Radiat Oncol 2011, 6:76. BioMed Central Full Text
• [17]Tse RV, Hawkins M, Lockwood G, et al.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
• [18]ICRU: Report 83: prescribing, recording and reporting intensity modulated photon beam therapy (IMRT) (ICRU report 83). International Commission on Radiation Units and Measurements, Washington, DC; 2010.
• [19]Hsu WC, Chan SC, Ting LL, et al.: Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol 2006, 36:93-99.
• [20]Krishnan S, Dawson LA, Seong J, et al.: Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 2008, 15:1015-1024.
• [21]Seong J, Park HC, Han KH, et al.: Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003, 27:30-35.
• [22]Skinner HD, Sharp HJ, Kaseb AO, et al.: Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol 2011, 50:1191-1198.
• [23]Yoon SM, Lim YS, Won HJ, et al.: Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012, 82:2004-2011.